211At-CD123 RIT

N/A

Report date: 2025/11/05 17:48:39

Base Information

Drug Name211At-CD123 RIT
Drug Alias Name[211At]astatine-based anti-CD123 radioimmunotherapy(Fred Hutchinson Cancer Research Center)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Astatine > 211At +[5] 
Mechanisms of ActionAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterUniversity Of Washington
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of WashingtonFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A